Top Stocks in the News: Venu Secures Major Non-Dilutive Capital, Lucid Teams with Uber on Robotaxis, XXII Gains Traction, Marker Expands Immunotherapy Manufacturing

July 17, 2025

DENVER, Colo., Jul 17, 2025 (247marketnews.com)- Shares of Venu (NYSE:VENU) are in focus after the company announced it has retained Texas Capital Securities as its exclusive financial advisor to arrange approximately $200 million in non-dilutive private debt commitments. The move follows a Strong Buy rating and $22.30 price target in a recent Cenorium analyst report, further validating investor interest in Venu’s expanding footprint in premium live entertainment infrastructure.

“We are thrilled to have Texas Capital Securities and their private capital advisory professionals join our team,” said JW Roth, Founder, CEO, and Chairman of Venu. “The music business is roaring and Venu continues to amass a significant backlog of luxury fire pit receivables, having sold over $75 million in 2024, and expected to reach $200 million in 2025.”

The $200 million in anticipated private capital will support the rapid buildout of Venu’s amphitheater developments in McKinney and El Paso, Texas, and Broken Arrow, Oklahoma, a core part of the company’s ambitious plan to develop 20 fan-first venues with 250,000 total seats by 2028. The facilities feature high-end amenities, including luxury firepit boxes and Aikman Clubs, named after NFL legend Troy Aikman, blending sports, music, and elevated fan experiences.

22nd Century Group (NASDAQ:XXII), a tobacco harm reduction pioneer, continues to see commercial momentum following new partner brand launches of its VLN reduced nicotine content cigarettes, including Smoker Friendly VLN and Pinnacle VLN.

VLN remains the only FDA-authorized combustible cigarette product to meet the agency’s proposed reduced nicotine standard of 0.7 mg/g. With its proprietary leaf containing an average of 0.5 mg/g, or 95% less nicotine than traditional products, the company is positioning itself to lead the transition to a lower-risk nicotine future.

Lucid (NASDAQ:LCID), Uber (NYSE:UBER), and Nuro unveiled a major collaboration to deploy 20,000+ fully autonomous premium robotaxis over the next six years, exclusively on the Uber platform. Built on Lucid’s Gravity SUV architecture and Nuro’s Level 4 autonomy system, the vehicles will be owned or operated by Uber or fleet partners, with commercial service expected to begin next year in a major U.S. city.

The first prototype is already operating autonomously at Nuro’s Las Vegas test track. This bold push into autonomous mobility underscores Uber’s evolving strategy to scale driverless ride-hailing and Lucid’s expansion beyond consumer EVs.

Marker Therapeutics (NASDAQ:MRKR), a clinical-stage immuno-oncology company, has entered into a manufacturing agreement with Cellipont Bioservices to scale up cGMP manufacturing of MT-601, its Multi-Antigen Recognizing T (MAR-T) cell therapy for relapsed lymphoma patients.

MT-601 has already shown promise in the Phase 1 APOLLO trial, with a 78% objective response rate and 44.4% complete response rate in early participants. The partnership with Cellipont will accelerate clinical supply, support potential pivotal trials, and help prepare for future commercial readiness.

Please click here to read Cenorium’s full Venu analyst report on 247marketnews.com.

Please go to https://247marketnews.com/venu-disclosure/ for additional 247marketnews.com VENU disclosure

About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.

24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.

CONTACT:
24/7 Market News
Editor@247marketnews.com

Related news for (VENU, XXII, LCID, UBER, MRKR)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.